In the general news, The missing Malaysian Boeing 777 jet continued to dominate news, as it turned into a hijacking investigation. Russia continue to invade Ukraine, seeming to have won the battle for Crimea. In the U.S., President Obama’s record low approval helped fuel a special election win for the GOP in congress: an election viewed as a referendum against Obamacare. In the senate, Senator Feinstein openly accused the CIA of spying on senate staff computers.
In healthcare business news, Charles River (CRL) acquire Galapagos (GLPG). A court invalidated Pfizer’s (PFE) Celebrex patent. Also, Gilead’s (GILD) CEO cashed in more than $160 Million worth of stock options last year, amidst critics who claim that Solvadi for HPC is too costly.
On the data front, Oxigene (OXGN) shares spiked more than 130% after drug Zybrestat, combined with Roche’s Avastin, to treat ovarian cancer met endpoints.
From the FDA, Geron (GERN) shares sank when the agency put a hold on trials for Imetelstat in Essential Thrombocythemia and Multiple Myeloma. Lastly, Regado’s (RGDO) anticoagulant REG1 was classified as Fast Track.